Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03007732 · ClinicalTrials.gov registry record · Phase 2

Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT

A Phase 2 study of Prostatic Neoplasms, sponsored by David Oh.

Completed
Registry status
Phase 2
Development phase
23
Enrollment target
1
Study location

NCT03007732: Completed Phase 2 study of Prostatic Neoplasms, sponsored by David Oh.

NCT03007732 is a Phase 2 study of Prostatic Neoplasms that has completed, run by David Oh. The registered enrollment target is 23 participants, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03007732, a Phase 2 study of Prostatic Neoplasms, has completed, sponsored by David Oh.

COMPLETED
Registry status
Phase 2
Development phase
23 participants
Enrollment target
1
Study location

Study Summary

This is a non-comparative open-label multicenter Phase 2 clinical trial combining stereotactic body radiation therapy (SBRT) and pembrolizumab with or without intratumoral SD-101 in participants with newly diagnosed hormone-naive oligometastatic prostate cancer.

Primary Outcome

Only participants in cohort 2, who achieve testosterone recovery to non-castrate levels (\>150 ng/dL) at 15 months, will be analyzed for the primary endpoint. The rate of PSA \< nadir + 2 ng/mL at 15 months from the start of radiotherapy and cycle 1, day 1 of pembrolizumab, among participants whose testosterone recovers to non-castrate levels (\>150 ng/dL). The point estimate of the rate of PSA \< nadir + 2 ng/mL will be obtained with its 95% confidence interval for participants by arm in cohort

Conditions Studied

Prostatic Neoplasms

Interventions

  • DRUG Pembrolizumab
  • DRUG Prednisone
  • DRUG Leuprolide acetate
  • DRUG Abiraterone Acetate
  • DRUG SD-101

Study Locations (1)

California

  • University of California San Francisco - San Francisco

Trial Details

FieldValue
Enrollment Target 23 participants
Start Date 2017-05-17
Est. Completion 2025-03-31
Phase Phase 2
David Oh

2 total trials

What the finished NCT03007732 record still lists

NCT03007732 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 23 participants, a relatively small participant target, below the 514-participant average among 65 other Prostatic Neoplasms trials with a reported enrollment target (96% lower).

The record links to 1 condition, with Prostatic Neoplasms appearing as the primary indexed condition, and to 5 interventions - of which Pembrolizumab is the first listed.

NCT03007732 reports a single indexed study location in California.

Frequently Asked Questions

What is clinical trial NCT03007732 about?

NCT03007732 is a clinical study titled "Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT". This is a non-comparative open-label multicenter Phase 2 clinical trial combining stereotactic body radiation therapy (SBRT) and pembrolizumab with or without intratumoral SD-101 in participants with newly diagnosed hormone-naive oligometastatic prostate cancer.

What is the current status of trial NCT03007732?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 23 participants. The study started on 2017-05-17. Estimated completion is 2025-03-31.

What conditions does trial NCT03007732 study?

This clinical trial studies the following conditions: Prostatic Neoplasms.

What interventions are being tested in trial NCT03007732?

The interventions under investigation include: Pembrolizumab (DRUG), Prednisone (DRUG), Leuprolide acetate (DRUG), Abiraterone Acetate (DRUG), SD-101 (DRUG).

Who is sponsoring clinical trial NCT03007732?

This trial is sponsored by David Oh, which has 2 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03007732 being conducted?

This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Prostatic Neoplasms

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT03007732's enrollment target sits among peer trials

23 56th of 65 higher than 10 of 65 other Prostatic Neoplasms trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Prostatic Neoplasms trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03616041 · 23 participants

    Capsule Endoscopy for Severe Hematochezia

  • NCT04348747 · 23 participants · Phase 2

    Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer

  • NCT04587687 · 23 participants · Phase 2

    Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma

  • NCT04715022 · 23 participants · Phase 1

    Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Related registry views

Source: ClinicalTrials.gov NCT03007732, the US trial registry maintained by the National Library of Medicine. NCT03007732 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.